International Urology and Nephrology

, Volume 48, Issue 11, pp 1873–1880 | Cite as

Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus

  • Qijin Zhu
  • Xiangming Qi
  • Yonggui WuEmail author
  • Kun Wang
Nephrology - Original Paper


Background and aim

Total glucosides of paeony (TGP), an active compound extracted from dried roots of Paeonia lactiflora Pall, have anti-inflammatory effects. This study investigated the efficacy and safety of TGP for treating diabetic kidney disease (DKD) in type 2 diabetes mellitus patients.


An open-label, prospective, randomized, parallel-group, single-site study involving 76 patients with DKD. Patients were randomized into two groups: losartan group (n = 38), treated with losartan 100 mg/day for 6 months and TGP group (n = 38), treated with TGP 1800 mg/day and losartan 100 mg/day for 6 months. Serum hs-CRP, MCP-1, and TNF-α were determined before and after treatment. Urinary albumin excretion rate (UAER), fasting blood glucose, serum creatinine, and lipid profiles were examined.


At the end-point, UAER decreased in the TGP group compared with baseline. UAER in the losartan group decreased to a level lower than before treatment. The rate of decline in the losartan group was significantly lower than the TGP group. There were no significant differences in serum creatinine and albumin levels between TGP and losartan groups at the end-point. Serum hs-CRP, MCP-1, and TNF-α levels were significantly lower in both groups after treatment. After treatment, serum hs-CRP, MCP-1, and TNF-α in the TGP group decreased more than the losartan group. Positive correlations were observed between UAER and hs-CRP, MCP-1, and TNF-α. No statistically significant difference in side effects was observed between groups.


Our study showed that TGP treatment could reduce the albuminuria and inflammatory markers in type 2 diabetes mellitus patients with DKD.


Diabetic kidney disease Total glucosides of paeony Albumin excretion rate Inflammation 



This study was funded by grants from the National Natural Science Foundation of China (No. 80270813).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Research Committee of the First Affiliated Hospital of Anhui Medical University and with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    (2003) USRDS: the United States Renal Data System. Am J Kidney Dis 42:1–230Google Scholar
  2. 2.
    Weir MR (2014) Salt, hypertension, and proteinuria in diabetic nephropathy. Lancet Diabetes Endocrinol 2:351–352CrossRefPubMedGoogle Scholar
  3. 3.
    Navarro-González JF, Mora-Fernández C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19:433–442CrossRefPubMedGoogle Scholar
  4. 4.
    Agrrawal NK, Kant S (2014) Targeting inflammation in diabetes: newer therapeutic options. World J Diabetes 5:697–710CrossRefGoogle Scholar
  5. 5.
    Ding ZK, Yang SF, Wu QF, Lu Y, Chen YY, Nie XL, Jie HY, Qi JM, Wang FS (2011) Therapeutic effect of total glucosides of paeony on lupus nephritis in MRL/lpr mice. Nan Fang Yi Ke Da Xue Xue Bao 31:656–660PubMedGoogle Scholar
  6. 6.
    Zhang HF, Xiao WG, Hou P (2011) Clinical study of total glucosides of paeony in patients with systemic lupus erythematosus. Zhongguo Zhong Xi Yi Jie He Za Zhi 31:476–479PubMedGoogle Scholar
  7. 7.
    Zhao M, Liang GP, Tang MN et al (2012) Total glucosides of paeony induces regulatoryCD4(+)CD25(+) T cells by increasing Foxp3 demethylation in lupus CD4(+) T cells. Clin Immunol 143:180–187CrossRefPubMedGoogle Scholar
  8. 8.
    Wang L, Lin J, Zhou Z et al (2011) Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells. PLoS ONE 6:e27289CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhou Q, Li ZG (2013) Pharmaceutical effects of total glucosides of peony and its application in autoimmune disease. Chin J New Drugs Clin Rem 22:687–691Google Scholar
  10. 10.
    Zhang MO, Wang YJ, Chen HY et al (2014) Efficacy and safety of Pafulin in treatment of mesangial proliferative nephritis. Zhejiang Clin Med J 36:924–927Google Scholar
  11. 11.
    Mo H, Chen YD (2014) A clinical study of total glucosides of paeony for treatment of patients with systemic lupus erythematosus accompanied by leucopenia. Chin J TCM WM Crit Care 21:104–107Google Scholar
  12. 12.
    Zheng YQ, Wei W, Zhu L, Liu JX (2007) Effects and mechanisms of Paeoniflorin, a bioactive glucoside from paeony root, on adjuvant arthritis in rats. Inflamm Res 56:182–188CrossRefPubMedGoogle Scholar
  13. 13.
    Liu DF, Wei W, Song LH (2006) Protective effect of paeoniflorin on immunological liver injury induced by bacillus Calmette-Guerin plus lipopolysaccharide: modulation of tumour necrosis factor-alpha and interleukin-6 MRNA. Clin Exp Pharmacol Physiol 33:332–339CrossRefPubMedGoogle Scholar
  14. 14.
    Mora C, Navarro JF (2005) The role of inflammation as pathogenic factor in the development of renal disease in diabetes. Curr Diab Rep 5:399–401CrossRefPubMedGoogle Scholar
  15. 15.
    Huang H, Chang EJ, Lee Y et al (2008) A genome-wide microarray analysis reveals anti-inflammatory target genes of paeonol in macrophages. Inflamm Res 57:189–198CrossRefPubMedGoogle Scholar
  16. 16.
    Su J, Zhang P, Zhang JJ, Qi XM, Wu YG, Shen JJ (2010) Effects of total glucosides of paeony on oxidative stress in the kidney from diabetic rats. Phytomedicine 17:254–260CrossRefPubMedGoogle Scholar
  17. 17.
    Wu Y, Ren K, Liang C, Yuan L, Qi X et al (2009) Renoprotective effect of total glucosides of paeony (TGP) and its mechanism in experimental diabetes. J Pharmacol Sci 109:78–87CrossRefPubMedGoogle Scholar
  18. 18.
    Zhou Z, Lin J, Huo R, Huang W, Zhang J et al (2012) Total glucosides of paeony attenuated functional maturation of dendritic cells via blocking TLR4/5 signaling in vivo. Int Immunopharmacol 14:275–282CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang CQ, Wu XX, Wu YG et al (2014) Effect of total glucosides of paeony on TRL signal pathway in the kidney from diabetic rats. Chin Pharmacol Bull 30:354–359Google Scholar
  20. 20.
    Zhang P, Zhang JJ, Su J, Qi XM, Wu YG, Shen JJ (2009) Effect of total glucosides of paeony on the expression of nephrin in the kidneys from diabetic rats. Am J Chin Med 37:295–307CrossRefPubMedGoogle Scholar
  21. 21.
    Nakagawa T, Goto H, Hikiami H, Yokozawa T, Shibahara N, Shimada Y (2007) Protective effects of keishbukuryogan on the kidney of spontaneously diabetic WBN/Kob rats. J Ethnopharmacol 110:311–317CrossRefPubMedGoogle Scholar
  22. 22.
    Liao H, Banbury LK, Leach DN (2007) Elucidation of danzhixiaoyao wan and its constituent herbs on antioxidant activity and inhibition of nitric oxide production. Evid Based Complement Altern Med 4:425–430CrossRefGoogle Scholar
  23. 23.
    Mezzano S, Aros C, Droguet A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J (2004) NF-kappa B activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19:2505–2512CrossRefPubMedGoogle Scholar
  24. 24.
    Currie G, McKay G, Delles C (2014) Biomarkers in diabetic nephropathy: Present and future. World J Diabetes 5:763–776CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Navarro JF, Mora C (2005) Role of inflammation in diabetic complications. Nephrol Dial Transplant 20:2601–2604CrossRefPubMedGoogle Scholar
  26. 26.
    Skundric DS, Lisak RP (2003) Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res 4:303–312CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 336:2058–2061CrossRefGoogle Scholar
  28. 28.
    Zain M, Awan FR (2014) Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy. Pak J Pharm Sci 27:1379–1391PubMedGoogle Scholar
  29. 29.
    Sharma AM, Weir MR (2011) The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med 123:109–121CrossRefPubMedGoogle Scholar
  30. 30.
    Fornoni A, Ijaz A, Tejada T et al (2008) Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 4(1):10–17CrossRefPubMedGoogle Scholar
  31. 31.
    Wu Y, Ren K, Liang C et al (2009) Renoprotective effect of total glucosides of paeony(TGP) and its mechanism in experimental diabetes. J Pharmacol Sci 109(1):78–87CrossRefPubMedGoogle Scholar
  32. 32.
    Niewczas MA, Gohda T, Skupien J et al (2012) Circulating TNF receptor 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23:507–515CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  1. 1.Department of Nephrology, The First Affiliated HospitalAnhui Medical UniversityHefeiChina

Personalised recommendations